|
|
|
RPRX Dividend History & Description — Royalty Pharma plc
Royalty Pharma is a buyer of biopharmaceutical royalties. The royalties in Co.'s marketed portfolio related to approved products include: cystic fibrosis franchise, which consists of Co.'s right to receive royalty payments on the sale of various products for use in the treatment of cystic fibrosis, including Kalydeco (ivacaftor), Orkambi (lumacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor and ivacaftor) and Trikafta/Kaftrio (elexacaftor, tezacaftor and ivacaftor); and Tysabri, which is a monoclonal antibody for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. When considering the Royalty Pharma plc stock dividend history, we have taken known splits into account, such that the RPRX dividend history is presented on a split-adjusted ("apples to apples") basis. Royalty Pharma plc dividend history is presented both in graphical/chart form, and as a RPRX dividend history data table along the right-hand column.
|
RPRX Stock Dividend HistoryThe RPRX dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable RPRX historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the RPRX dividend history record. Also see the RPRX stock dividend history data table along the right-hand column below.
|
|
|
|
Strong Buy (3.79 out of 4)
73rd percentile
|
|
|